(NASDAQ: IMNM) Immunome's forecast annual revenue growth rate of 71.79% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Immunome's revenue in 2025 is $10,938,000.On average, 4 Wall Street analysts forecast IMNM's revenue for 2025 to be $475,696,397, with the lowest IMNM revenue forecast at $252,335,751, and the highest IMNM revenue forecast at $794,422,555. On average, 3 Wall Street analysts forecast IMNM's revenue for 2026 to be $2,352,465,300, with the lowest IMNM revenue forecast at $225,361,930, and the highest IMNM revenue forecast at $4,517,680,070.
In 2027, IMNM is forecast to generate $4,951,001,463 in revenue, with the lowest revenue forecast at $3,080,236,411 and the highest revenue forecast at $7,683,188,562.